2-{4-[(2,4-dichloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-N,N-diphenyl-acetamide | 866562-67-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-{4-[(2,4-dichloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-N,N-diphenyl-acetamide
• 英文别名: 2-[4-[(2,4-dichlorophenyl)-phenylmethyl]piperazin-1-yl]-N,N-diphenylacetamide
• CAS: 866562-67-6
• 化学式: C₃₁H₂₉Cl₂N₃O
• 分子量: 530.497
• InChiKey: GGKXNHJATNHIDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  26.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-[(2,4-dichlorophenyl)(phenyl)methyl]piperazine 、 2-bromo-N,N-diphenylacetamide 在 碳酸氢钠 作用下， 以 乙腈 为溶剂， 生成 2-{4-[(2,4-dichloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-N,N-diphenyl-acetamide
  参考文献：
  名称：

  Structure–activity relationships of diphenylpiperazine N-type calcium channel inhibitors

  摘要：

  A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.008

文献信息

• Diarylamine derivatives as calcium channel blockers
  申请人：Pajouhesh Hassan

  公开号：US20050227999A1

  公开（公告）日：2005-10-13

  Compounds which are derivatives of diarylamine substituted piperazine and amino-piperidine are useful in treating conditions mediated by calcium ion channel activity.

  衍生自二芳基胺基哌嗪和氨基哌啶的化合物在治疗受钙离子通道活性介导的疾病方面具有用处。
• DIARYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
  申请人：Neuromed Pharmaceuticals, Ltd.

  公开号：EP1745042A1

  公开（公告）日：2007-01-24
• [EN] DIARYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS<br/>[FR] DERIVES DE DIARYLAMINE UTILISES COMME BLOQUANTS DES CANAUX CALCIQUES
  申请人：NEUROMED TECH INC

  公开号：WO2005097779A1

  公开（公告）日：2005-10-20

  N-diarylaminoalkyl-substituted piperazine/4-aminopiperidine compounds of formula (1) are disclosed, wherein each of A and B is independently a 6-membered aromatic or nonaromatic, carbocyclic or heterocyclic moiety or is an aminoalkyl and wherein one and only one of A and B may be H or alkyl (1-8C) or wherein A and B together form an optionally substituted 6-membered aromatic of nonaromatic, carbocyclic or heterocyclic moiety; R1 is H or alkyl (1-8C), Z is N or CHNR2 wherein R2 is H or alkyl (1-8C), X is straight chain alkylene (1-4C) wherein optionally at least one carbon adjacent to a nitrogen is in the form of C=0; each R3 is an independent substituent; n=0-2; Ar is a six-membered aromatic or heteroaromatic ring; wherein each cyclic moiety included in A or B each Ar moiety in formula (1) may be substituted by one or more substituents. These compounds and salts or conjugated thereof are able to block N-type and T-type calcium channels and are useful for treating conditions mediated by calcium ion channel activity such as chronic pain.
• Structure–activity relationships of diphenylpiperazine N-type calcium channel inhibitors
  作者：Hassan Pajouhesh、Zhong-Ping Feng、Yanbing Ding、Lingyun Zhang、Hossein Pajouhesh、Jerrie-Lynn Morrison、Francesco Belardetti、Elizabeth Tringham、Eric Simonson、Todd W. Vanderah、Frank Porreca、Gerald W. Zamponi、Lester A. Mitscher、Terrance P. Snutch

  DOI：10.1016/j.bmcl.2010.01.008

  日期：2010.2

  A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.